Skeletal Muscle as a Therapeutic Target for Natural Products to Reverse Metabolic Syndrome by Mazibuko-Mbeje, Sithandiwe Eunice et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Skeletal Muscle as a Therapeutic Target for Natural
Products to Reverse Metabolic Syndrome
Sithandiwe Eunice Mazibuko-Mbeje,
Phiwayinkosi V. Dludla, Bongani B. Nkambule,
Nnini Obonye and Johan Louw
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.78687
Abstract
Natural compounds, especially polyphenols have become a popular area of research mainly
due to their apparent health benefits. Increasing the phenolic content of a diet, apart from its
antioxidant benefit, has a beneficial effect on signaling molecules involved in carbohydrate
and lipid metabolism. These effects could potentially protect against metabolic syndrome, a
cluster of metabolic complications such as obesity, insulin resistance and type 2 diabetes that
is characterized by a dysregulated carbohydrate, and lipid metabolism. Research continues
to investigate various natural compounds for their amelioration of impaired signaling mech-
anisms that may lead to dysregulated metabolism to find means to improve the life expec-
tancy of patients with metabolic syndrome. In this chapter, a systematic search through
major databases such as MEDLINE/PubMed, EMBASE, and Google Scholar of literature
reporting on the ameliorative potential of commonly investigated natural products that
target skeletal muscle to ameliorate metabolic syndrome associated complications was
conducted. The selected natural products that are discussed include apigenin, aspalathin,
berberine, curcumin, epigallocatechin gallate, hesperidin, luteolin, naringenin, quercetin,
resveratrol, rutin, and sulforaphane.
Keywords: skeletal muscle, metabolic syndrome, insulin resistance, type 2 diabetes,
natural products
1. Introduction
A considerable amount of interest has been placed on the discovery of novel naturally occur-
ring plant-derived compounds for the treatment and prevention of various diseases. Bioactive
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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compounds of plant origin have long been shown to possess strong ameliorative properties
against various communicable and noncommunicable diseases [1, 2]. For example, since its
traditional use during the 1950s, artemisinin, an antimalarial qinghao derived lactone, has been
the leading therapy for the treatment of Plasmodium falciparum malaria worldwide [3]. Simi-
larly, the traditional use of galegine, an alkaloid isolated from Galega officinalis, led to the
discovery of biguanide class of antidiabetic medications such as metformin [4]. Agents such
as metformin are effective at lowering blood glucose levels and combating complications
associated with insulin resistance (IR), the major characteristic of the metabolic syndrome [5].
However, the continued rise in the mortality of diabetic patients warrants an investigation into
alternative therapies to reduce the burden of noncommunicable diseases. Naturally derived
compounds such as polyphenols are increasingly explored for their therapeutic potential to
reverse IR and thus decrease the risk of developing the metabolic syndrome. This may even-
tually lead to an increased life expectancy of diabetic individuals [6]. Thus, due to its modula-
tory effect of glucose and lipid metabolism, skeletal muscle has been a target to a growing
number of therapeutic interventions in an effort to reverse IR and improve the management of
metabolic syndrome [7, 8]. Here, we systematically assessed the available literature on the
ameliorative potential of some of the prominent natural products against IR associated com-
plications. A systematic search was conducted on all major databases such as MEDLINE/
PubMed, EMBASE, and Google Scholar, for available literature reporting on the ameliorative
properties of some of the prominent natural compounds including apigenin, aspalathin, ber-
berine, curcumin, epigallocatechin gallate, hesperidin, luteolin, naringenin, quercetin, resvera-
trol, rutin, and sulforaphane against IR related to the development of metabolic syndrome. The
search was conducted from inception until the end of January 2018, gray literature such as
abstract proceedings and pre-prints were also included. There were no language restrictions
implemented while review articles were screened for primary findings.
2. Apigenin
Apigenin (PubChem CID: 5280443) is a natural flavone (40,5,7-trihydroxyflavone) with the
molecular formula C15H10O5 (MW 270.24 g/mol) that is abundantly present in fruits and
vegetables, including parsley, chamomile, and celery (Figure 1) [9]. Apigenin was identified
as the main yellow dye compound in the flowers of Delphinium Zalil as early as the 1890s [10],
and its bioavailability and metabolism profile has been studied as far back as the 1970s [11].
Figure 1. The chemical structure of apigenin (40,5,7-trihydroxyflavone).
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Although pharmacokinetic studies show that apigenin has low bioavailability [12, 13], this
compound has been detected in rat plasma after intravenous bolus administration [14], and it
was demonstrated that human intestinal microbiota might contribute to its metabolism [15]. The
knownmetabolites of apigenin detected in the urine of rats consist of p-hydroxyphenylpropionic
acid, p-hydroxycinnamic acid, and p-hydroxybenzoic acid metabolites [11] while it is known
glucosides include apiin, apigenin, vitexin, isovitexin, and rhoifolin.
In relation to its biological activities, increasing studies have demonstrated that apigenin
displays a broad spectrum of anticarcinogenic properties as reviewed by Sung et al. [16]. Some
of the well-studied mechanisms associated with the chemo-preventative capabilities of
apigenin include its anti-inflammatory activity, its ability to suppress cell proliferation and
oxidative stress, as well as its modulatory effect of autophagy and apoptosis [16, 17]. Interest-
ingly, similar mechanisms have also been implicated in the development and aggravation of IR
and its related complications. In a recent study, Jung et al. [18] showed that in addition to
reducing circulating free fatty acids (FFAs), total cholesterol, and apolipoprotein B levels,
apigenin modulated transcriptional factors linked with the development of obesity and related
metabolic disturbances in high fat diet (HFD)-induced mice. This study showed that apigenin
upregulated the expression of genes responsible for the regulation of beta-oxidation, oxidative
phosphorylation, as well as electron transport chain and cholesterol homeostasis, which are all
essential target sites for the control of substrate usage in cells. Although limited studies are
reporting on its effect on skeletal muscle, two recent studies have shown that apigenin can
regulate skeletal muscle function. For instance, Choi et al. [19] showed that this flavone
improved mitochondrial function and exercise capacity by reducing the expression of atrophic
genes such as RING-finger protein-1 and Atrogin 1 in mice fed HFD. Jang et al. [20] demon-
strated that in C2C12 cells and skeletal muscle of C57BL/6 mice, this flavone promoted hyper-
trophy and myogenic differentiation by regulating protein arginine methyltransferase 7
(Prmt7)-peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α)-G
protein-coupled receptor 56 (GPR56) pathway, as well as the Prmt7-p38-myoD pathway.
Although additional studies are required to further assess the impact of apigenin in the
modulation of metabolic disease-related complications through the regulation of skeletal mus-
cle function, the two aforementioned studies suggest that this flavone has a potential to protect
against skeletal muscle weakness associated with metabolic complications.
3. Aspalathin
Aspalathin (PubChem CID: 11282394) is a natural C-glucosyl dihydrochalcone (30-β-D-
glucopyranosyl-20,3,4,40,60- pentahydroxydihydrochalcone) with the molecular formula
C21H24O11 (MW 452.412 g/mol) (Figure 2) [21]. Although aspalathin was known to be uniquely
found in rooibos [22], recent evidence has shown that this C-linked dihydrochalcone glucoside
can be detected in trace amounts in two other species of Acacia pendula [23]. Aspalathin is
considered to have a poor bioavailability profile in different experimental settings as reviewed by
Muller et al. [24] and Johnson et al. [25]. While Stalmach et al. [26], using high-performance liquid
chromatography-mass spectrometry method, showed that O-methyl-aspalathin-O-glucuronide
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and eriodictyol-O-sulfate were the main metabolites excreted following ingestion of rooibos
extract containing 10-fold higher levels of aspalathin in human subjects. In addition, a recent
study by Bowles et al. [27] showed that aspalathin can be absorbed and metabolized to mostly
sulfate conjugates detected in the urine of mice. However, additional evidence is required to
establish the pharmacokinetic profile of aspalathin.
Relevant to its biological activity, the initial evidence demonstrated that aspalathin possess
strong antioxidant properties by scavenging 2,2-diphenyl-β-picrylhydrazyl (DPPH) radical
in vitro [28]. This effect was important since experimental and clinical studies support the
notion that drug compounds that enhance intracellular antioxidant properties can further
exhibit a wide range of beneficial effects against the development of metabolic syndrome [29].
In addition to its robust antioxidant activity [28, 30–34], aspalathin can ameliorate inflamma-
tion [35–39], protect cardiac cells exposed to high glucose concentrations [40–44], and also
display glucose lowering properties [45–50]. In addition to work by our group [46, 48], studies
conducted by Kawano et al. [51] and Son et al. [50] have reported on the effect of pure aspal-
athin or an aspalathin rich green rooibos extract on the signaling mechanisms that regulate
glucose and lipid metabolism in skeletal muscle. Activation of 5' AMP-activated protein kinase
(AMPK), an important kinase in the regulation of energy production, as well as increasing the
expression and translocation of glucose transporter (GLUT) 4 have been the key molecular
targets by aspalathin in the skeletal muscle. Thus, although additional evidence such as assessing
the therapeutic effect of this dihydrochalcone on skeletal muscle biopsies of insulin-resistant
human subjects is still necessary, its aforementioned potential to target AMPK, and improve
glucose uptake is of major importance for future therapeutic development.
4. Berberine
Berberine (PubChem CID: 2353) is a quaternary alkaloid (5,6-Dihydro-9,10-dimethoxybenzo[g]-
1,3-benzodioxolo[5,6-a]quinolizinium)withthemolecular formulaC20H18NO4
+ (MW336.37g/mol)
that is present in several plants including Hydrastis canadensis, Xanthorhiza simplicissima, Phellod-
endron amurense, and Berberis aristata (Figure 3) [52]. Berberrubine, thalifendine, demethy-
leneberberine, and jatrorrhizine are some of the major metabolites detected in plasma following
the administration of berberine in rats,with the liver and intestinal bacteria identified to participate
in the metabolism, and disposition of this compound in vivo [53]. Although a number of factors,
including it being hydrophilic in nature and its containment of quaternary ammonium groups
contribute to the low bioavailability of berberine [54]. Interestingly, the absorption of berberine in
the small intestine can be enhanced by d-α-tocopheryl polyethylene glycol 1000 succinate [55].
Figure 2. The chemical structure of aspalathin (30-β-D-glucopyranosyl-20,3,4,40,60- pentahydroxydihydrochalcone).
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Therefore, further research is required tobetterunderstandand informonmechanisms that canadd
to our current knowledge on the bioavailability of berberine, which is crucial in improving its
efficacy in vivo.
Berberine has a long history of medicinal use in traditional Chinese and Native American
medicine [56] and has demonstrated a number of beneficial effects against metabolic complica-
tions, including amelioration of IR. Berberine demonstrated an enhanced effect to reduce body
weight and raise plasma triglyceride levels while improving glucose tolerance and insulin action
in both type 2 diabetic (db/db) mice and in FHD fed rats [57]. Interestingly, similar to aspalathin,
an increase of glucose uptake through activation of AMPK as well as enhanced translocation of
GLUT4 in skeletal muscle remains important in the ameliorative potential of berberine against IR
[58–62]. However, it has been reported that berberine can alter muscle metabolism by altering
mitochondrial function, resulting in the development of muscle atrophy in normal, and diabetic
(db/db) mice [63]. Although the results were not in human subjects, these findings remain
relevant since loss of muscle mass is an important feature that occurs in type 2 diabetic patients,
especially in older individuals [64]. These results suggest that precaution should be taken when
using these quaternary alkaloids, especially considering the toxicity of high doses [65]. In addi-
tion to acting by targeting the mitochondria [65], another mechanism by which berberine can
reverse IR include downregulating toll-like receptor 4 (TLR4)/inhibitor of nuclear factor kappa-B
kinase subunit beta (IKKbeta)/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) inflammation signaling pathway, leading to reduced inflammation [66].
5. Curcumin
Curcumin, also known as diferuloylmethane (PubChem CID: 969516; (1E,6E)-1,7-Bis (4-hydroxy-
3-methoxyphenyl) hepta-1,6-diene-3,5-dione), is a major polyphenolic derivative of turmeric
(Curcuma longa) with the molecular formula C21H20O6 (MW 368.39 g/mol) (Figure 4) [67]. A single
oral dose administration of curcumin can lead to the detection of its metabolites, glucuronide, and
sulfate conjugates in plasma of human subjects [68]. Although is considered to have a safety
profile, curcumin displays poor bioavailability profile that is coupled with quick metabolism and
systemic removal [69]. However, recent developments such as blocking of metabolic pathways by
Figure 3. The chemical structure of berberine (5,6-dihydro-9,10-dimethoxybenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium).
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concomitant administration with other agents, conjugation, and modification of structure, as well
as modulation of route and medium of administration are some of the explored approaches to
improve the bioavailability of curcumin as reviewed by Prasad et al. [70]. Indeed, increasing
research over the past 30 years has focused on exploring the pharmacokinetics, safety profile,
and efficacy of this natural product in order to enhance its therapeutic profile in humans [71].
An increasing number of reviews has been published to keep track of the cumulative literature
informing on the therapeutic potential of curcumin, including anticancer, antioxidant, anti-
inflammatory, and antibacterial activities [70–72]. Relevant to its effect on skeletal muscle
function. A study published in 2005 by Farid et al. [73] showed that curcumin failed to inhibit
NF-κB activity, leading to its inability to ameliorate loss of muscle mass in the soleus. How-
ever, in a follow-up study published in 2008, curcumin presented enhanced effect in blocking
sepsis-induced muscle proteolysis, at least in part by inhibiting NF-κB, and p38 activities in
rats [74]. In L6 or C2C12 myotubes exposed to high palmitate concentrations as a model of IR,
curcumin reversed IR by increasing glucose and FFA oxidation, at least in part by mediating
LKB1-AMPK pathways, as well as suppressing insulin receptor substrate 1 (IRS-1) Ser307 and
protein kinase B (AKT) phosphorylation [75–77]. Although similar evidence has been
supported by in vivo experiments on skeletal muscle tissue of either diabetic or nondiabetic
rodents [75, 77], curcumin displays an enhanced capacity to protect against oxidative stress
associated complications by improving mitochondrial biogenesis, and other antioxidant mech-
anisms [78–81]. This involves activation of the nuclear factor (erythroid-derived 2)-like 2
(NRF2) [82], an essential intracellular antioxidant response element that is a target of various
natural products aiming to reduce metabolic disease-associated complications.
6. Epigallocatechin gallate
Epigallocatechin gallate (PubChem CID: 65064) is an ester of epigallocatechin and gallic
acid ([(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate,
with the molecular formula C22H18O11 (MW 458.375 g/mol), that is abundantly found in tea
(Figure 5) [83]. Due to the popularity of green tea and as one of its major components,
epigallocatechin gallate remains one of the highly consumed polyphenolic compounds [84].
Although it is detectable in its original form in human plasma after oral administration [85],
epigallocatechin gallate is considered to have very low oral bioavailability profile as reviewed
by Mereles and colleagues [86]. Although additional evidence is required to improve its
Figure 4. The chemical structure of curcumin ((1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione).
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bioavailability, there has been an extensive exploration of this polyphenolic compound for its
chemopreventive properties. Among the 10 polyphenols present in green tea, epigallocatechin
gallate was found to exhibit the most antiproliferative and antiapoptotic effects [87].
It has already been established that epigallocatechin gallate can ameliorate complications
linked with the development of the metabolic syndrome, by improving insulin sensitivity in
both obese rodents and patients [88–90]. The enhanced therapeutic effect of this catechin has
been associated with the modulation of various signaling pathways, including targeting of
genes involved in cell survival, FFA regulation, mitochondrial energetics, intracellular antiox-
idant response, and others as reviewed by Singh and colleagues [91]. A number of studies have
demonstrated several mechanisms associated with the ameliorative effect of epigallocatechin
gallate on IR and associated complications in skeletal muscle. In addition to strengthening
muscle integrity [92–94], accumulative data has been presented that this catechin can improve
insulin sensitivity by enhancing glucose uptake, reduce lactate concentrations, enhancing
mitochondrial capacity and stimulating beta-oxidation in cultured cells, or rodents as well as
obese human subjects [95–100]. Inhibition of oxidative stress, activation of AMPK, increased
expression of PGC-1α, NAD-dependent protein deacetylase sirtuin-1 (SIRT1), nuclear respira-
tory factor 1, medium chain acyl coA decarboxylase, uncoupling protein 3 (UCP3), AKT, and
peroxisome proliferator-activated receptor alpha (PPARα) are some of the mechanisms
targeted by epigallocatechin to enhance skeletal muscle function in a diseased state [101–104].
7. Hesperidin
Hesperidin (PubChem CID: 10621) is a flavanone glycoside ((2S)-5-hydroxy-2-(3-hydroxy-4-
methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-
methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one) with the molecular for-
mula C28H34O15 (MW 610.565 g/mol) that is present in high amounts in citrus fruits (Figure 6)
Figure 5. The chemical structure of epigallocatechin gallate ([(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-
3-yl] 3,4,5-trihydroxybenzoate).
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[105]. Although it has a low bioavailability due to the rutinoside moiety attached to the
flavonoid [106], hesperidin can be converted to glucuronides and sulfoglucuronides, which
have been shown to be excreted in urine nearly 24 hours after the orange juice ingestion [107].
In a randomized controlled trial, Nielsen et al. [108] demonstrated that removal of the rham-
nose group to yield hesperetin-7-glucoside improved the bioavailability of the aglycone
hesperetin. Suggesting that additional interventions are required to improve the bioavailability
of citrus flavonoids such as hesperidin.
Increasing data has supported the notion that hesperidin possesses increased potential to
lower raised blood glucose and lipid levels in various models of type 2 diabetes [109–111].
When administered in rats subjected to swimming exercise, this citrus flavonoid improved the
biochemical and antioxidant profile of the animals [112]. This compound may induce its
therapeutic effect through the regulation of genes implicated in insulin signaling such as
insulin receptor substrate 1, GLUT2/4, and those linked with lipid metabolism, including sterol
regulatory element–binding protein 1c (SREBP-1c), fatty acid synthase (FAS) and acetyl-CoA
carboxylase [113]. Although data on its effect on skeletal muscle is currently limited, it can
reverse IR by reducing muscle glycogen content and ischemia–reperfusion injury while pro-
moting myogenic differentiation through the activation of MyoD-mediated myogenin expres-
sion in cultured cells and animals [109, 114, 115].
8. Luteolin
Luteolin (PubChem CID: 5280445) is a flavone glycoside (2-(3,4-Dihydroxyphenyl)- 5,7-
dihydroxy-4-chromenone) with the molecular formula C15H10O6 (MW 286.239 g/mol) that is
rich in various dietary sources such as fruits, vegetables, and teas (Figure 7) [116]. As with
most flavonoids, during its metabolism luteolin is broken down to its glucuronides, which can
eventually pass through intestinal mucosa as shown by Yasuda and colleagues [117].
Although studies reporting on the pharmacokinetic profile of luteolin in human subjects are
limited, this flavone is quickly absorbed in rats and can be detected in urine and feces while
showing a slow elimination rate [118]. Furthermore, luteolin from peanut hull extract can be
easily absorbed compared to the pure compound, with its absorption more efficient in the
Figure 6. The chemical structure of hesperidin ((2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one).
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jejunum and duodenum than in the colon and ileum [119]. Alternatively, luteolin-loaded solid
lipid nanoparticles prepared by hot microemulsion ultrasonic technique can also improve the
solubility and increase the compound concentration in plasma of rats [120].
In addition to its strong antioxidant effects [121], in vitro experiments have provided evidence
that luteolin possesses chemopreventive and anti-inflammatory properties [122, 123]. Hydroxyl
groups and 2–3 double bond remain key structural features of luteolin that are linked to its
enhanced therapeutic effect [124]. Recent studies show that this flavone attenuates hepatic
steatosis and IR by upregulating PPARγ protein expression and activating AMPKα1 signaling,
which may be linked to the improvement in circulating FFA levels in diet-induced obese mice
[125, 126]. However, only a few studies have reported on the effect of luteolin on the skeletal
muscle. Available literature has reported on its effect in preventing lipopolysaccharide-induced
muscle atrophy, oxidative stress-induced tissue injury and inflammation, partly through regula-
tion of atrogin-1/MAFbx expression, and c-Jun N-terminal kinases (JNK) phosphorylation
reported on [127–129].
9. Naringenin
Naringenin (PubChem CID: 932) is a flavanone (5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-
4-one) with the molecular formula C15H12O5 (MW 272.256 g/mol) that is also predominantly
found in citrus fruits (Figure 8) [130]. The chemical structure of naringenin comprises three
hydroxy groups at the 40, 5, and 7 carbons while its glycoside, naringin contains an additional
disaccharide neohesperidose that is linked via its carbon end. Although naringenin can be
Figure 7. The chemical structure of luteolin (2-(3,4-dihydroxyphenyl)- 5,7-dihydroxy-4-chromenone).
Figure 8. The chemical structure of naringenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one).
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detected as monoglucuronides in plasma and urine after ingestion of orange fruit juice in
human subjects [131], the bioavailability of naringenin can be influenced by its glycosidic
moiety. Felgines et al. [132] demonstrated that kinetics of absorption of naringenin and
naringenin-7-glucoside was similar. In addition, naringenin-7-rhamnoglucoside exhibited a
delay in its intestinal absorption, resulting in decreased bioavailability after ingestion in rats.
On the other hand, complexation of naringenin with hydroxypropoyl-β-cyclodextrin has been
another viable alternative to improve the bioavailability of naringenin, which is important to
enhance its therapeutic potential [133].
Naringenin is among the well-studied citrus flavonoids shown to prevent complications
associated with IR and the metabolic syndrome. Its role in preventing the deterioration in
skeletal muscle mass and protecting against metabolic associated complication is summa-
rized. In low-density lipoprotein (LDL) receptor–null (Ldlr/) mice fed HFD, this flava-
none reduced fasting hyperinsulinemia, improved glucose utilization and increased insulin
sensitivity through regulation of SREBP-1c–mediated lipogenesis [134]. It stimulated glu-
cose uptake but failed to have a significant effect on basal or insulin-stimulated AKT
phosphorylation while significantly increasing AMPK phosphorylation/activation in cul-
tured L6 myotubes [135]. Bhattacharya and colleagues showed that naringenin stimulates
glucose uptake, indicating a dependence on GLUT4 activity as well as phosphatidy-
linositol-4,5-bisphosphate 3-kinase (PI3K) and/or p38MAPK activity [136]. Maintenance of
muscle mass by reducing muscle diacylglycerol content, improving hyperinsulinemia, pro-
moting phosphorylation of p38/MAPK via estrogen receptor beta (ERβ), lowering reactive
oxygen species (ROS) production, and enhancing tyrosine phosphorylation are other mech-
anisms associated with protective effect of naringenin in either cultured cells or in vivo
animal models [137–140].
10. Quercetin
Quercetin (PubChem CID: 5280343) is classified as a flavonol (2-(3,4-dihydroxyphenyl)-3,5,7-
trihydroxy-4H-chromen-4-one) with the molecular formula C15H10O7 (MW 302.238 g/mol) that
is abundantly found in various fruits and vegetables (Figure 9) [141]. Quercetin is one of the
most abundant dietary flavonoids that is rapidly metabolized to glucuronides and sulfates that
can be detected in plasma and urine [142]. Although oral bioavailability of quercetin remains
Figure 9. The chemical structure of quercetin (2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one).
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low, the type of sugar moiety attached to its structure may affect its absorption. This has been as
demonstrated with quercetin glycosides from onion which have a higher absorption rate com-
pared to apple-derived quercetin [143, 144]. Quercetin-4’-O-glucoside and quercetin-3-O-
rutinoside (rutin) are one the accomplished glycosides of quercetin, and their absorption rate
and extent can be influenced by plant matrix as demonstrated by Graefe and colleagues [145].
However, it is clear that further investigations into improvement strategies for pure quercetin
aglycone are required to improve the therapeutic potential of this flavonol.
Quercetin exhibits a wide range of biological functions. Although Stewart et al. [146] failed to
show any beneficial effect of quercetin against IR in diet induced-obese mice, other researchers
have shown that this flavonol plays a major role in modulating several signaling pathways to
reverse metabolic syndrome and improve skeletal muscle function, either in vitro on cultured
cells or in vivo in animals and samples from human subjects [148–168]. In L6 myotubes and
skeletal muscle of genetical modified (ob/ob) mice, quercetin improved insulin sensitivity by
increasing GLUT4 expression [147]. Several studies using different experimental models have
also demonstrated the positive effect of quercetin in improving skeletal muscle insulin sensi-
tivity through enhanced uptake of glucose, and reducing oxidative stress or inflammation-
induced damage, with modulation of tumor necrosis alpha (TNF-α), AKT, peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and AMPK as prime
pathways involved in the process [148–158]. The therapeutic potential of quercetin extends to
its preventative effect against ischemia–reperfusion injury, as well as strengthening muscle
fibers through the modulation of calcium homeostasis, and enhancing intracellular antioxi-
dants [159–168].
11. Resveratrol
Resveratrol (PubChem CID: 445154) is a phytoalexin stilbenoid (3,5,40-trihydroxy-trans-
stilbene) with the molecular formula C14H12O3 (MW 228.247 g/mol) that is present in abundant
amounts in various food sources such as grapes, blueberries, and red wine (Figure 10) [169].
Upon ingestion, resveratrol can be metabolized to form conjugated sulfates and glucuronides,
namely resveratrol monosulfate, monosulfate dihydroresveratrol, and monoglucuronide
dihydroresveratrol, as reviewed by Gambini and colleagues [170]. Although the bioavailability
of resveratrol is considered low, it can vary depending on the method of administration and
type of dietary source ingested [171]. The dimethyl ether analog of resveratrol, pterostilbene,
Figure 10. The chemical structure of resveratrol (3,5,40-trihydroxy-trans-stilbene).
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has been shown to exhibit a higher bioavailability, in terms of total plasma levels of both the
parent compound and metabolites than does resveratrol [172]. However, Li et al. [173] showed
that intravenous and oral pharmacokinetic characteristics of trans-resveratrol can be improved
through encapsulating with PP123 self-assembling lecithin-based mixed polymeric micelles.
Suggesting that alternative methods to improve the bioavailability of resveratrol are required,
which may translate to enhanced therapeutic potential in vivo.
Resveratrol has displayed a variety of antidiabetic effects in rodent models. In addition,
resveratrol attenuates thermal hyperalgesia, cold allodynia, as well as raised serum lipid levels
[174–176]. In diabetic individuals, resveratrol administration is associated with significantly
improved glucose and insulin control [177]. The systematic search of evidence linking resver-
atrol and IR in skeletal muscle revealed up to 18 studies published between 2007 and 2017,
with 9 papers produced between 2016 and 2017, suggesting that this phytoalexin stilbenoid is
increasingly explored for therapeutic effect against metabolic associated complications.
Although Williams and colleagues showed no effect on insulin signaling pathways [178],
stimulation of glucose uptake by resveratrol in cultured C2C12 cells or skeletal muscle has
been linked with activation of extracellular signal-related kinase/p38/PI3K [179]. Its effect in
promoting glucose uptake and improving insulin sensitivity was also associated with
increased NAD-dependent protein deacetylase sirtuin-1 (SIRT1) expression, activation of
AMPK while abolishing phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/
2), JNK, and IκB kinase α/β (IKKα/IKKβ) [180–190]. Other documented beneficial effect of
resveratrol includes inhibiting ischemia–reperfusion injury through its potent antioxidant
properties [191], reducing cell proliferation through upregulating PGC-1α [192], promoting
muscle regeneration and attenuating the impact of ROS [193], and elevated forearm skeletal
muscle mitochondrial capacity [194].
12. Rutin
Rutin (PubChem CID: 5280805) is a glycoside combining the flavonol quercetin and the
disaccharide rutinose (2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[α-L-rhamnopyranosyl-
(1!6)-β- D-glucopyranosyloxy]-4H-chromen-4-one) with the molecular formula C27H30O16
(MW 610.521 g/mol) that is found in many plants and fruits, as well as tea infusions (Figure 11)
[195]. Upon oral administration, rutin can be metabolized into sulfates and glucuronides of
quercetin that are detected in blood, whereas unchanged forms of rutin and quercetin were not
detected [142, 196]. Although quercetin glycosides from onions demonstrate an enhanced absorp-
tive capacity than pure aglycones [143, 144], some studies have showed that rutin has a lower oral
absorption rate than quercetin [142, 197]. However, as with the use of natural deep eutectic
solvents [198], alternative methods to improve the absorptive capacity of rutin is tested to
improve therapeutic effect in vivo.
Like quercetin, rutin exhibits a wide variety of biological properties, mostly attributed to its
strong antioxidant properties [199, 200]. It is accomplished that rutin displays enhanced potential
Muscle Cell and Tissue - Current Status of Research Field186
to improve insulin sensitivity by regulating genes involved in glucose and lipid metabolism such
as GLUT4, PPARγ, and tyrosine phosphatase 1B in cultured cells or skeletal muscle of rodents
[201–204]. However, from the study by Zyma et al. [205], that demonstrated that rutin induces
conformational changes in the myosin structure of skeletal muscle of rabbits accompanied by an
increase in ATPase activity, accumulative evidence has supported muscle strengthening capacity
of this polyphenol. For example, Su et al. [206] presented data showing that rutin promoted
skeletal muscle endurance capacity by modulating markers of mitochondrial biogenesis such as
PGC-1α and SIRT1 expression in ICR mice subjected to a weight-loaded forced swim test. These
findings were further supported by data showing that rutin increased the mitochondrial size and
mitochondrial DNA content as well as gene expression related to mitochondrial biogenesis, such
as PGC1-α, NRF-1, transcription factor A, and SIRT1 [207, 208].
13. Sulforaphane
Sulforaphane (PubChem CID: 5350) is an isothiocyanate (1-isothiocyanato-4-methylsulfi-
nylbutane) with the molecular formula C6H11NOS2 (MW 177.28 g/mol) that is found in
cruciferous vegetables such as cabbages, broccoli, and brussels sprouts (Figure 12) [209].
Although sulforaphane displays a dose-dependent pharmacokinetic behavior, as higher
doses show reduced absorptive potential, lower doses of the compound can be rapidly
absorbed in rats following intravenous administration, with the absolute bioavailability
being able to reach 82% [210]. In human subjects consuming fresh broccoli sprouts or the
broccoli sprout extract, with each estimated to provide 200 μmol sulforaphane daily, the
Figure 12. The chemical structure of sulforaphane (1-isothiocyanato-4-methylsulfinylbutane).
Figure 11. The chemical structure of rutin (2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[α-L-rhamnopyranosyl-(1!6)-β-D-
glucopyranosyloxy]-4H-chromen-4-one).
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compound metabolites were found to be three times higher in plasma and urine of sprout
consumers, suggesting enhanced sulforaphane absorption from sprouts [211]. Therefore,
dietary form and dosing schedule of sulforaphane may influence impact absorption and
therapeutic potential in human subjects.
Sulforaphane has received a considerable interest due to its ability to simultaneously control
multiple cellular targets involved in various metabolic complications. For instance, in rats fed
HFD, this isothiocyanate has displayed an enhanced hypoglycemic potential as well as the
elevation of GLUT3 expression in the cerebral cortex and hypothalamus, leading to improved
glucose tolerance [212]. Other studies [213, 214] have supported the beneficial effect of sulfo-
raphane or its stable precursor glucoraphanin, to reverse IR, mostly through its robust antiox-
idant properties. In skeletal muscle, sulforaphane has exhaustive exercise-induced muscle
damage, reducing muscle glycogen content, and enhanced exercise endurance capacity
through inhibition of pro-inflammatory response and enhancing antioxidant response by
upregulating NRF2 expression [215–220].
14. Conclusions
Natural compounds have gained popularity for their potential beneficial effect to fight
metabolic diseases due to their less adverse effect compared to synthetic drugs. Furthermore,
natural compounds serve as a valuable source for the discovery of new drugs. Currently,
knowledge shows that natural compounds can ameliorate IR, however, the gap in scientific
evidence of plant-derived therapeutic benefits still exist due to the slow rate of translation of
animal studies findings into human clinical trials. In this chapter, evidently reported the
great potential and the future promise of natural compounds for the management and
treatment of metabolic disorders, specifically IR, obesity, and T2D. Therefore, further
research is required to assess the use of natural compounds alone or in combination with
well know antidiabetic drugs might result in synergistic and enhanced effects in combating
metabolic diseases.
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